{"id":983933,"date":"2026-07-23T00:28:31","date_gmt":"2026-07-23T04:28:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/"},"modified":"2026-07-23T00:28:31","modified_gmt":"2026-07-23T04:28:31","slug":"dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/","title":{"rendered":"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program<\/b><\/p>\n<p><i>Participation advances the company\u2019s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment<\/i><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260722426337\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260722426337\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/4\/Dexcom_TEMPO.jpg\" alt=\"Dexcom Announced as First Participant Selected for FDA&apos;s TEMPO Digital Health Devices Pilot Program\" \/><\/p>\n<p style=\"font-size:85%\">Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program<\/p>\n<\/div>\n<p>\nParticipation in the TEMPO pilot will allow Dexcom to implement an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual health information such as nutrition, physical activity, sleep and stress, to deliver more personalized insights for healthcare professionals and program eligible users. The program leverages Dexcom&#8217;s industry-leading clinician software platform, to provide healthcare professionals with a more comprehensive view of metabolic health, helping them monitor progress and personalize therapy at a population level. The program is also intended as an aid in the screening of prediabetes and Type 2 diabetes through integrated digital health metrics and may contribute to improving glycemic control and lowering HbA1c in people with prediabetes.<\/p>\n<p>\nThe pilot will support Dexcom&#8217;s efforts to generate real-world evidence evaluating how glucose biosensing technology and AI-enabled digital health programs advance earlier intervention strategies, including research focused on prediabetes and Type 2 diabetes, and future efforts to collect evidence for broader cardiometabolic health outcomes.<\/p>\n<p>\n\u201cGlucose is one of the body&#8217;s most powerful health signals, providing immediate insight into a person\u2019s overall health,\u201d said Jake Leach, president and CEO of Dexcom. \u201cTransforming this data into more personalized, proactive screening and preventive care has the potential to help millions of people make meaningful lifestyle changes before disease develops, while also generating the evidence needed to expand access to these technologies. Being the first company selected by the FDA to participate in this pilot program marks another first for Dexcom and underscores our continued leadership in innovation.&#8221;<\/p>\n<p>\nThe FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health technologies that support chronic disease management while collecting real-world performance data. The initiative is part of the agency&#8217;s broader effort to accelerate access to innovative digital health solutions while maintaining patient safety.<\/p>\n<p>\nDexcom&#8217;s participation builds on the company&#8217;s continued investment in digital health and expanding the role of glucose biosensing across the continuum of care. The company continues to advance technologies that help people and healthcare professionals better understand the relationship between glucose and lifestyle factors to enable more personalized health decisions.<\/p>\n<p>\nTo learn more about the portfolio of Dexcom glucose biosensors, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54575426&amp;newsitemid=20260722426337&amp;lan=en-US&amp;anchor=Dexcom.com&amp;index=1&amp;md5=440c365906e6785bcc1f120ef7d918da\">Dexcom.com<\/a>.<\/p>\n<p><b><span class=\"bwuline\">About Dexcom<\/span><\/b><\/p>\n<p>\nDexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.<\/p>\n<p>\nDexcom. Discover what you\u2019re made of. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dexcom.com%2F&amp;esheet=54575426&amp;newsitemid=20260722426337&amp;lan=en-US&amp;anchor=Dexcom.com&amp;index=2&amp;md5=ecf25d785d0e6b9a644393e7edbdd26b\">Dexcom.com<\/a>.<\/p>\n<p>\nCategory: IR<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260722426337r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260722426337\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260722426337\/en\/<\/a><\/span><\/p>\n<p><b><span class=\"bwuline\">Media Contact<br \/>\n<\/span><\/b><br \/>Nadia Conard<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mediarelations@dexcom.com\">mediarelations@dexcom.com<\/a><\/p>\n<p><b><span class=\"bwuline\">Investor Contact<br \/>\n<\/span><\/b><br \/>Sean Christensen<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:sean.christensen@dexcom.com\">sean.christensen@dexcom.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health FDA Diabetes Artificial Intelligence Medical Devices Health Technology Technology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/3\/Dexcom_TEMPO.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/1474219\/3\/New_Dexcom_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program Participation advances the company\u2019s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260722426337\/en\/ Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program Participation in the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-983933","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dexcom Announced as First Participant Selected for FDA&#039;s TEMPO Digital Health Devices Pilot Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dexcom Announced as First Participant Selected for FDA&#039;s TEMPO Digital Health Devices Pilot Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program Participation advances the company\u2019s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260722426337\/en\/ Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program Participation in the &hellip; Continue reading &quot;Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T04:28:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/4\/Dexcom_TEMPO.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program\",\"datePublished\":\"2026-07-23T04:28:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/\"},\"wordCount\":630,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260722426337\\\/en\\\/2858228\\\/4\\\/Dexcom_TEMPO.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/\",\"name\":\"Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260722426337\\\/en\\\/2858228\\\/4\\\/Dexcom_TEMPO.jpg\",\"datePublished\":\"2026-07-23T04:28:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260722426337\\\/en\\\/2858228\\\/4\\\/Dexcom_TEMPO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260722426337\\\/en\\\/2858228\\\/4\\\/Dexcom_TEMPO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/","og_locale":"en_US","og_type":"article","og_title":"Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Market Newsdesk","og_description":"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program Participation advances the company\u2019s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260722426337\/en\/ Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program Participation in the &hellip; Continue reading \"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-23T04:28:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/4\/Dexcom_TEMPO.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program","datePublished":"2026-07-23T04:28:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/"},"wordCount":630,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/4\/Dexcom_TEMPO.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/","name":"Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/4\/Dexcom_TEMPO.jpg","datePublished":"2026-07-23T04:28:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/4\/Dexcom_TEMPO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260722426337\/en\/2858228\/4\/Dexcom_TEMPO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dexcom-announced-as-first-participant-selected-for-fdas-tempo-digital-health-devices-pilot-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dexcom Announced as First Participant Selected for FDA&#8217;s TEMPO Digital Health Devices Pilot Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/983933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=983933"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/983933\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=983933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=983933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=983933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}